Harrow also announced that IOPIDINE 1% and MAXITROL are now commercially available; Harrow intends to commercialize MOXEZA 0.5% at a later date. Harrow purchased these medicines in December 2021 ...

Back to Healio The new drug application transfer process for Iopidine 1%, Maxitrol 0.1% and Moxeza 0.5% is complete, Harrow Health announced in a press release. Harrow acquired the ...

IOPIDINE® is a short-term adjunctive therapy for patients with chronic glaucoma to prevent or control intraocular pressure*, 1 including after selective laser therapy, a form of laser eye surgery ...